New pill shows promise against tough lung cancer
Disease control
Recruiting now
This study tests a new daily pill, TRI-611, for adults with advanced ALK-positive non-small cell lung cancer that has not responded to other treatments. The trial has two parts: first, finding the safest dose, and second, seeing how well it shrinks tumors in different groups base…
Phase: PHASE1, PHASE2 • Sponsor: TRIANA Biomedicines, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC